• A written informed consent should be signed by a subject or his/her legal representative before any study-related procedures are performed;

• Subjects with histologically or cytologically confirmed locally advanced or metastatic advanced solid tumors harboring KRAS p.G12C mutation who have failed or lack standard-of-care (SOC) or are unwilling to undergo or intolerant to SOC;

• Expected survival ≥ 3 months;

• Subjects must have at least one measurable lesion as defined by RECIST v1.1. If no measurable lesion untreated with radiation is selected as the target lesion, a lesion treated with radiation ≥ 4 weeks before the first dose and with progression confirmed by radiography may be selected as the target lesion;

• Eastern Cooperative Oncology Group(ECOG) performance status 0-1;

• The organ functions of subjects meet the criteria for the following laboratory parameters at screening;

• Subjects must be able to swallow oral medications without gastrointestinal abnormalities that significantly affect drug absorption